YAP/TAZ as mechanobiological signaling pathway in cardiovascular physiological regulation and pathogenesis
Authors:
Open Access
- 9 August 2024
- journal article
- Published by Elsevier in Mechanobiology in Medicine
- Vol. 2 (4)
Abstract
No abstract availableKeywords
Funding Information
- NIH (7 R15 HL147214-02)
- NSF
- National Science Foundation (2304667)
This publication has 119 references indexed in Scilit:
- Development of LM98, a Small‐Molecule TEAD Inhibitor Derived from Flufenamic AcidChemMedChem, 2021
- VGLL4 inhibits YAP1/TEAD signaling to suppress the epidermal squamous cell carcinoma cancer phenotypeMolecular Carcinogenesis, 2021
- Neuronal Hippo signaling: From development to diseasesDevelopmental Neurobiology, 2020
- Matrix stiffness controls cardiac fibroblast activation through regulating YAP via AT1RJournal of Cellular Physiology, 2020
- The role of Hippo signaling pathway and mechanotransduction in tuning embryoid body formation and differentiationJournal of Cellular Physiology, 2020
- Association of Cardiovascular Disease With Premature Mortality in the United StatesJAMA Cardiology, 2019
- Mst1 deletion reduces septic cardiomyopathy via activating Parkin‐related mitophagyJournal of Cellular Physiology, 2019
- Oxidized low‐density lipoprotein promotes vascular endothelial cell dysfunction by stimulating miR‐496 expression and inhibiting the Hippo pathway effector YAPCell Biology International, 2019
- WW and C2 domain–containing proteins regulate hepatic cell differentiation and tumorigenesis through the hippo signaling pathwayHepatology, 2018
- Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo PathwayChemMedChem, 2017